Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is a biopharmaceutical company focused on developing innovative therapies for non-alcoholic steatohepatitis (NASH), leveraging significant research partnerships with AbbVie and BI to derive most of its revenue. The company's lead product candidate, lanifibranor, has shown promising clinical results, including a 42% improvement in fibrosis compared to a 24% improvement with placebo, marking it as a potential best-in-class therapy in the NASH landscape. Management's positive outlook is reinforced by the candidate's ability to target both MASH resolution and fibrosis improvement, suggesting strong market adoption potential, particularly among patients who are non-responsive to existing therapies.

Bears say

Inventiva SA is facing a challenging financial outlook primarily due to a significant net loss of €175.9 million, or €1.62 per share, highlighting the company's ongoing financial struggles. The main clinical program, lanifibranor, is currently in Phase III development, and any issues related to efficacy or safety discovered in these early stages could severely impact the company's stock performance. Additionally, the risks associated with clinical trial failures, regulatory delays, and potential difficulties in accessing equity capital markets further exacerbate the uncertainties surrounding Inventiva's operational and financial stability.

Inventiva S.A. (IVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Inventiva S.A. (IVA) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.